ARCHIVES

NCI Advisors Criticize a Biomarker Study Touted as High Priority for NCI and FDA.

This article is from The Cancer Letter archive.

Vol. 33 No. 27 | July 13, 2007

Download PDF Visit The Full Archive

Related Articles

Professional Societies: AACR Presents Awards At Annual Meeting

April 18, 1997

Conversation With The Cancer Letter: Seffrin To Retire After Restructuring ACS

January 24, 2014

NCCN Admits Two New Member Institutions

March 22, 2013

In Brief: Hammer Hears A Claim for The $1 Million Wynder’s Theory On Japan’s Colon Cancer Rates: Hamburgers

March 19, 1982

Five-Fold Increase in Chordoma Risk Linked to Common Gene Variant

October 26, 2012

NCI Proposes New Grants and Centers For Molecular Target-Based Therapeutics

March 26, 1999